Roger S. McIntyre, M.D., FRCPC
- Professeur de psychiatrie et de pharmacologie, Université de Toronto, Canada
- Chef, Unité de psychopharmacologie des troubles de l'humeur http://www.mdpu.ca/
- Président et directeur général, Brain and Cognition Discovery Fondation (BCDF), Toronto, Canada
- Directeur, Depression and Bipolar Support Alliance (DBSA), Chicago, Illinois, États-Unis
- Professeur et boursier Nanshan, Université médicale de Guangzhou, Guangzhou, Chine
- Professeur adjoint Collège de Médicine, Université de Corée, Seoul, République de Corée
- Professeur clinique Université d'État de New York (SUNY) Upstate Medical University, Syracuse, New York, États-Unis
- Professeur clinicien Département de psychiatrie et de neurosciences de l’école de médecine Université de la Californie , Riverside, Californie, États-Unis
Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre is the founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE).
Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019 and 2020 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has published more than 700 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre has also contributed extensively to clinical practice guidelines. For example, Dr. McIntyre is the lead author the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. In addition, Dr. McIntyre is also the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders as well as the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
Joshua D. Rosenblat, MD, MSc, FRCPC
- Professeur adjoint, clinicien-chercheur, Département de psychiatrie, Université de Toronto
- Psychiatre du personnel, Unité de psychopharmacologie des troubles de l'humeur (MDPU)
- Centre familial Poul Hansen pour la dépression
- Toronto Western Hospital, Réseau universitaire de santé
Le Dr Joshua Rosenblat est directeur médical et chercheur au Centre canadien d'excellence en traitement rapide (CRTCE). Le Dr Rosenblat est également clinicien-chercheur à l'Unité de psychopharmacologie des troubles de l'humeur (MDPU) du Toronto Western Hospital et de l'Université de Toronto. Le Dr Rosenblat a traité des centaines de patients avec des perfusions de kétamine pour la dépression résistante au traitement, le trouble bipolaire, la suicidalité et le SSPT. Il continue également de mener de nombreuses études de recherche pour mieux comprendre comment l'utilisation de la kétamine peut être optimisée en psychiatrie pour permettre un soulagement rapide et durable des symptômes et une récupération fonctionnelle complète.
Le principal objectif clinique du Dr Rosenblat est la dépression unipolaire et bipolaire résistante au traitement. Son objectif de recherche est la conduite d'essais cliniques pour identifier et évaluer de nouvelles interventions psychopharmacologiques pour les troubles de l'humeur susceptibles d'améliorer considérablement les résultats pour les patients. Les nouveaux traitements actuels d'intérêt comprennent la kétamine, d'autres modulateurs du glutamate, des psychédéliques et des agents anti-inflammatoires neuroprotecteurs. Il s'intéresse également à cibler des domaines spécifiques de symptômes trans-diagnostiques, tels que la cognition, l'anhédonie (par exemple, le manque de plaisir et de motivation) et la suicidalité, qui ne répondent pas aussi bien aux traitements actuellement disponibles. Il est l'auteur et le co-auteur de plus d'une centaine d'articles de revues et de chapitres de manuels dans des revues prestigieuses, telles que le New England Journal of Medicine, JAMA Psychiatry, l'American Journal of Psychiatry et le Journal of Clinical Psychiatry. Il a reçu de nombreuses bourses et prix locaux, nationaux et internationaux pour ses recherches sur les troubles de l'humeur. Le Dr Rosenblat est également activement impliqué dans l'enseignement aux étudiants en médecine et aux résidents aux niveaux local et national. New England Journal of Medicine, JAMA Psychiatry, the American Journal of Psychiatry and the Journal of Clinical Psychiatry. He has received numerous local, national and international grants and awards for his research in mood disorders. Dr. Rosenblat is also actively involved in teaching medical students and residents locally and nationally.
Dr. Rosenblat studied medicine at the University of Western Ontario and then completed his residency training in Psychiatry at the University of Toronto. During his residency training, he served as the Chief Resident of the Clinician-Scientist Program and completed a Masters of Science in the Department of Pharmacology, studying the antidepressant effects of ketamine in special populations.